Biorasi Revenue and Competitors

Miami, FL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Biorasi's estimated annual revenue is currently $62.9M per year.(i)
  • Biorasi's estimated revenue per employee is $201,000

Employee Data

  • Biorasi has 313 Employees.(i)
  • Biorasi grew their employee count by -4% last year.

Biorasi's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief StaffReveal Email/Phone
3
Head Global FeasibilityReveal Email/Phone
4
VP Project ManagementReveal Email/Phone
5
SVP, People and CultureReveal Email/Phone
6
SVP Operations & Head StrategyReveal Email/Phone
7
SVP, Commercial OperationsReveal Email/Phone
8
VP, Clinical OperationsReveal Email/Phone
9
VP, Data Sciences and BiometricsReveal Email/Phone
10
VP, Medical and Scientific AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$33.8M12515%N/AN/A
Add Company

What Is Biorasi?

Biorasi is a contract research organization (CRO) widely recognized for delivering success in complex clinical trials. This is possible through TALOS, an innovative operating model that unifies systems and teams with a powerful project management methodology to ensure high quality delivery. Overall, Biorasi balances power, time, acceptance, cost, and service level to optimize the delivery of clinical studies. With TALOS as our foundation, we leverage three elements to deliver success: - Full-service capabilities seamlessly integrated for high quality delivery - Global footprint across North America, Western and Eastern Europe, Asia, Australia, and Latin America, leveraging an optimal set of venues for every study - Therapeutic area expertise allowing optimized delivery of complex Phase I-IV studies Contact us now to learn more about how we can help you manage your most complex studies. http://www.biorasi.com/contact-us

keywords:N/A

N/A

Total Funding

313

Number of Employees

$62.9M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Biorasi News

2022-03-22 - Therapeutic Solutions selects Biorasi to run phase 3 trial of JadiCell for COVID-19

Therapeutic Solutions International (OTCPK:TSOI) said it selected Biorasi as the contract research organization (CRO) to run a phase 3 trial...

2021-05-11 - Biorasi Receives ISO 9001:2015 Certification for Quality Management

Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the achievement of ISO 9001:2015 certification. By earning this ISO accreditation, Biorasi has demonstrated dedication to the practice of quality assurance within the clinical trials industry and co ...

2021-03-02 - Biorasi’s Jimmy El Hokayem Appointed to Scientific Advisory Board for the Foundation for Angelman Syndrome Therapeutics

MIAMI--(BUSINESS WIRE)--Mar 2, 2021-- Biorasi, a leading global full-service contract research organization (CRO), has announced the appointment of Jimmy El Hokayem, Ph.D., head of the company’s Neurology and Regenerative Medicine Center of Excellence to the Scientific Advisory Board (SAB) for ...

2019-05-02 - Biorasi Rescue Effort Doubles CNS Trial Enrollment Rate

Instead of simply doing more of what the primary CRO was doing on behalf of the sponsor, Biorasi leveraged their extensive patient network and Talos™ ...

2018-12-13 - Biorasi closes PE deal, next stage to be 'vastly different' as ...

Biorasi plans to scale several aspects of its global CRO business following a PE investment – and while it does not plan to “buy size,” smaller ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$82.4M31428%N/A
#2
$39.3M3147%N/A
#3
$78.9M31425%N/A
#4
$106.3M3157%N/A
#5
$39.6M3177%N/A